Table 1.
RT | Sequence 5′‐3′ | Sequencing | Sequences 5′‐3′ |
---|---|---|---|
2.06neg | tttagtaaaaagaccacc | 0.67+ | cctaaggattacgctgatgcttttgc |
4.26neg | catacttttgcgcatc | 1.26+ | ttcgcaggaacttgtcttgcaagc |
6.18neg | agaaaacctacaccag | 2.52+ | tagaggaatgtcacagcttggtgc |
8.18neg | gtaaagaatgtactaaac | 3.04+ | tacaccaatgtcacagcttggtgc |
10.10neg | cacagttgtgtgcactaactcaaag | 3.10+ | ctctcgatgttgtgaatttaccatctgg |
12.10neg | ctccataagaatcctg | IB4.6+a | gtacggatgaagtaatagaagcttc |
14.13neg | taaaacttggttgttcc | 4.80+ | tgattgtgatgttgtgaatttaccatctgg |
16.10neg | ttcacataaagcatcaac | IB5.15nega | catcagtatcaggtgttaacttataag |
QX18.10neg | catagaagaagaatggcatagctttc | 5.32+ | ctattagtcttagggcaatatggg |
19.73neg | caaaatgcattactcgc | IB5.70+a | gtgtggtttatttacacaagtaatccag |
22.51neg | catatcttctttttgacc | 6.53+ | gttaaacctacagcatatgcttacc |
24.08neg | tttgaatcattaaacagac | IB6.7nega | ctaatcgttctgaaagtgcctgatcaag |
26.24neg | ccaagatacatttccag | IB7.15+a | ctttataacaagatctggtgctaaac |
27.89neg | Ttgctctaactctatac | 7.17+ | aatgctcctccggtagtatggaag |
Dta‐Adaptnegb | gcatctcgaggcttgtggcttttttttttttttttttttta | IB8.2nega | caacccaaactagcattattgtaaacac |
Dtc‐Adaptnegb | gcatctcgaggcttgtggctttttttttttttttttttttc | 8.60+ | gtatgatggcaacgagtttgttgg |
Dtg‐Adaptnegb | gcatctcgaggcttgtggctttttttttttttttttttttg | IB8.61nega | taccaacaaactcgttgccatc |
PCR | Sequence 5′‐3′ | 9.26+ | cctgtcactatgcgttctaatggtac |
0.06+ | gcgctagatttccaacttaacaaaacg | 10.60+ | ggtaaatccacctaaaactgtgtggg |
2.03neg | gacttgcgaaacaagatgccaaatgcc | 11.13+ | gaagttagatagcatggagagacg |
1.92+ | tggaggcttgcatatggaaaagtgcg | 12.64+ | gacttaaagtcagaagtaacagctg |
4.20neg | ggtataaagaggatttctttatcctcaagatcatg | 13.18+ | gatctcctcaagtatgattatactgagg |
4,10+ | cggaggatggtgttaaataccgc | QX13.90+ | gaggtgacgtctaaatattttgaatg |
6.08neg | caaataatattagaaagaccaaataaagccaattcc | 14.69+ | caaggtcttgtagcagatatttctgg |
5.90+a | gactatggtaaagactcatttgacg | 15.25+ | aagtgttgctatgaccatgtcatgc |
8.05neg | cctggtttagtatactcacatacactacc | IB15.60+a | ggtgcagcttggtgattttacctttg |
7.97+ | cctaatggtgttaggcttatagttcc | IB16.40nega | ctataaccttgaaacactgacgtg |
10.10neg | gtactaaagactacaggatcataccattg | QX16.80neg | gaatcagctgtaacacagaatataac |
10.02+ | cagttattattggagtttgtgctgaag | 16.62+ | catgaaagtggctcagcctacaac |
12.08neg | gaatcctgatccggagttggacttggc | 17.18+ | caacatgttttataacacgtgatgaggc |
12.01+ | gtggcagcaggtaatcaacctttagg | 18.02neg | ctgcttgacattgggtactactggattc |
14.12neg | ataaaacttggttgttccaataactacagg | 18.18+ | taacctacctggttgtaatggtgg |
14.05+ | gtgtctatcctttctactatgactaataggc | 18.71+ | gaagagaaatattcgcacactgcc |
16.09neg | cacataaagcatcaacagctgcatgag | 19.67nega | gtattgacagagttgtgtatactttggc |
QX15.06+ | gatgattgcactcgcatagtacctc | 19.46+ | gtaacagtgtcaattgattaccatagc |
QX18.10neg | catagaagaagaatggcatagctttc | 19.97+ | gatagccaataatggcaatgatgacg |
17.62+a | tactcaggcttatgcttgttggaagc | IB20.40+a | cattgtttatagtgtctcttttgtttgcac |
19.67neg | gtattgacagagttgtgtatactttgcc | IB21.70nega | gtcacaaattgcccttatgtaagttatgg |
19.46+ | gtaacagtgtcaattgattaccatagc | IB21.95+a | ccagcagtttgtagtttctggtgg |
22.26neg | tccatacgcgtttgtatgtactcatctg | IB23.60nega | cacgtgcagtgatgtagtaactacc |
IB21.95+ | ccagcagtttgtagtttctggtgg | QX24.20neg | ctacttacactgtttcaattgttttctc |
IB24.07neg | gaatcattaaacagactttttaggtctg | IB24.70+a | gtactcttggtactgaacaagcag |
23.99+ | cattatgcctctaatgagtaagtgtgg | IB25.60nega | ctcttgaaaagagagcatgaaacaaagagg |
26.24nega | ccaagatacatttccag | QX27.20a,b | cctacatgtctatcgccaggg |
26.02+ | gaaaagcgcgaatttatctgagagaagg | ||
27.83neg | catagccaattaaacttaacttaaactaaaatttagctc | ||
26.49+ | gatagccaagatggtatagtgtggg | ||
Adapt negb | gcatctcgagggttgtggc |
Primer names generally indicate approximate binding positions in the 624I genome.
Coding and anticoding sense primers are labelled + and neg, respectively.
aIndicates primers designed for the 624I IBV strain sequencing based on the newly determined flanking sequences. bIndicates primers used for the retrotranscription, amplification, and sequencing of the 3′END of the genome.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.